Positive ZEPHYR Trial Results Fail to Impress Investors as MapLight Stock Plunges
MapLight ZEPHYR trial: BID dose hits primary endpoint & cognitive goals, but QD misses; shares plunge over 60% on mixed schizophrenia data.
/ 4 items
#MPLT↓
Wall Street Goes Bullish on Two Biotech Stocks: INBX and MPLT
Stifel & Needham back INBX & MPLT: promising cancer & brain drugs, strong safety, big market potential.
Schizophrenia Focus Pays Off — Canaccord Starts MPLT at Buy, Sees $35 Value on ML-007 Alone
Canaccord Genuity starts coverage on MapLight Therapeutics (MPLT) with Buy rating and $35 price target.
MapLight Therapeutics Gains from Bristol Myers’ ADEPT-2 Study Update
MapLight Therapeutics sees upside as Bristol Myers continues ADEPT-2 Alzheimer’s psychosis trial despite site irregularities, with potential catalysts for 2026.